Cancer BiologyOncoImmunologyPeer-reviewed
Targeting the Atypical Chemokine Receptor 2 (ACKR2) improves the benefit of anti-PD-1 immunotherapy in melanoma
Muhammad Zaeem Noman, Martyna Szpakowska, Malina Xiao…·Bassam Janji
This study shows that targeting ACKR2 enhances anti-PD-1 immunotherapy efficacy in melanoma by improving the tumor microenvironment and immune cell infiltration.